


EGFR-IN-71

Cat. No.:	HY-150781
CAS No.:	2676155-98-7
Molecular Formula:	C ₁₆ H ₉ ClIN ₃
Molecular Weight:	405.62
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EGFR-IN-71 is a potent narrow spectrum epidermal growth factor receptor (EGFR) inhibitor with IC ₅₀ values of 3.7 μM. EGFR-IN-71 can be used for researching chordoma ^[1] . EGFR-IN-71 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.								
IC₅₀ & Target	IC ₅₀ : 3.7 μM (EGFR) ^[1]								
In Vitro	<p>EGFR-IN-71 (compound 41) (0-100 μM; 72 h) has inhibitory activity against U-CH1, U-CH2, CH22, UM-Chor1, U-CH12 and U-CH7 chordoma cell lines^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>U-CH1, U-CH2, CH22, UM-Chor1, U-CH12 and U-CH7</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Exhibited inhibitory activity against U-CH1, U-CH2, CH22, UM-Chor1, U-CH12 and U-CH7 chordoma cell lines with IC₅₀s of 9.1 μM, 16 μM, 0.48 μM, 25 μM, 0.96 μM and 8.0 μM, respectively.</td> </tr> </table>	Cell Line:	U-CH1, U-CH2, CH22, UM-Chor1, U-CH12 and U-CH7	Concentration:	0-100 μM	Incubation Time:	72 h	Result:	Exhibited inhibitory activity against U-CH1, U-CH2, CH22, UM-Chor1, U-CH12 and U-CH7 chordoma cell lines with IC ₅₀ s of 9.1 μM, 16 μM, 0.48 μM, 25 μM, 0.96 μM and 8.0 μM, respectively.
Cell Line:	U-CH1, U-CH2, CH22, UM-Chor1, U-CH12 and U-CH7								
Concentration:	0-100 μM								
Incubation Time:	72 h								
Result:	Exhibited inhibitory activity against U-CH1, U-CH2, CH22, UM-Chor1, U-CH12 and U-CH7 chordoma cell lines with IC ₅₀ s of 9.1 μM, 16 μM, 0.48 μM, 25 μM, 0.96 μM and 8.0 μM, respectively.								

REFERENCES

[1]. Bieberich AA, et al. Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform. Sci Rep. 2022 Jul 27;12(1):12820.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA